AKT1 and mucinous adenocarcinoma: Additionally, the mutation rate of RAS/RAF/MAPK and PI3K/AKT pathways in mucinous adenocarcinoma (with more than 50% of mucinous component) is higher than that in non-mucinous adenocarcinoma (42).